NCT01504516CompletedPhase 1
Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10mg in Healthy, Adult, Human Subjects Under Fed Condition.
Dr. Reddy's Laboratories Limited1 site in 1 country25 target enrollmentStarted: October 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Area under curve (AUC)
Study Overview
Brief Summary
This is an open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, oral bioequivalence study.
Detailed Description
The study was an open label, balanced, randomized, two-treatment, two-period, two sequence,single dose, crossover, oral bioequivalence study of Donepezil Hydrochloride tablets 10mg of Dr. Reddy's Laboratories Limited, India comparing with that of ARICEPT® (containing Donepezil Hydrochloride) tablets 10mg of Pfizer Inc, New York, 10017 in healthy, adult, human subjects under fed condition. 28 subjects are enrolled in the study, 3 subjects are withdrawn from the study and 25 subjects are completed the study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Provide written informed consent.
- •Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg.
- •Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight in Kg/height in m
- •Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician / investigator to be of no clinical significance).
- •Female Subjects
- •Of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
- •Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
Exclusion Criteria
- •Incapable of understanding the informed consent.
- •Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.
- •Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.
- •Oral temperature is below 95.0°F or above 98.6°F.
- •Pulse rate below 50/min or above 100/min.
- •History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs.
- •Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.
- •Consumption of grapefruit for the past ten days prior to the check-in, in each period.
- •Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period.
- •Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period.
- •Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period.
- •Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing.
- •Clinically significant abnormalities and / or with significant diseases.
- •Confirmed positive in alcohol screening.
- •Confirmed positive in selected drug of abuse.
- •Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study.
- •Confirmed positive in urine pregnancy test.
- •Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study.
Arms & Interventions
Donepezil Hydrochloride10 mg Tablets
Experimental
Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
Intervention: Donepezil Hydrochloride (Drug)
Aricept 10 mg Tablets
Active Comparator
Aricept 10 mgTablets of Pfizer Inc
Intervention: Aricept (Drug)
Outcomes
Primary Outcomes
Area under curve (AUC)
Time Frame: Pre-dose 0.5,0.75,1,1.5,2,2.5,3,3.5,4,4.5,5,5.5,6,7,8,9,10,12,16,24,36,48,72,96,120,144,168,192,216,240 and 264 hours post-dose
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting ConditionHealthyNCT01504503Dr. Reddy's Laboratories Limited26
Completed
Phase 1
Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fed ConditionHealthyNCT01511718Dr. Reddy's Laboratories Limited26
Completed
Phase 1
Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting ConditionHealthyNCT01511705Dr. Reddy's Laboratories Limited26
Completed
Phase 1
Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting ConditionsHealthyNCT03706300Dr. Reddy's Laboratories Limited80
Completed
Phase 1
Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fed ConditionHealthyNCT01671722Dr. Reddy's Laboratories Limited43